In vitro studies have shown that tumor cells harboring the most prevalent HER2YVMA are able to activate EGFR in a ligand-independent fashion and irrespective of the presence of an activating EGFR mutation [22,28]. The gene discussed is EGFR; the disease is neoplasm.